Eko Health developed an AI algorithm that, combined with noninvasive heart tests, may be able to accurately identify pulmonary hypertension.

Eight-year-old Abbie Hampshire is the first to benefit from a private tour of a York hospital's on-site laboratories as part ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Columnist Anna Jeter reflects on her mental health needs and various treatment approaches since being diagnosed with PH at ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

High blood pressure is a major risk factor for heart disease. Here are some common questions you may have about blood ...

The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 millionReceived CE Mark for LungFit PH® in ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Long-term exposure to PM2.5, PM10, NO2 and ozone (O3) air pollution is associated with more hospital admissions for lower respiratory tract infections in adults.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...